2017 年5 月(no71）の記事要旨と参考文献 · 1 2017 年5...

1

2017 年 5 月(No71）の記事要旨と参考文献

参考文献はアクセスが容易になるように、できる限りネットへのリンクをつけたものにして

います（特に PubMed アブストラクトへリンクできるよう）

P50

2

Editorial p51

Free http://www.npojip.org/chk_tip/71-Editorial.pdf

総説 p52-53

参考文献

1) マンモグラフィーによる乳がんスクリーニング(Part 1). Prescr Int. 2015, 24(158): 72-73. (抄訳: 薬のチェックTIP. 2016, 16(63): 21-23.)2) 同(Part2,3): 同上2015, 24(159):99-101,24(162):186-190(抄訳: 同,2016, 16(66):92-94)3) 薬のチェックTIP 編集委員会、マンモグラフィー検診は受けなくてよい. 薬のチェックTIP.2016: 16(67): 1184) Donker M, Litière S, Werutsky G, Julien JP et al. Breast-conserving treatment with or withoutradiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence,from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4054-9.https://www.ncbi.nlm.nih.gov/pubmed/240437395) Wapnir IL, Dignam JJ, Fisher B et al. Long-term outcomes of invasive ipsilateral breast tumorrecurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl

3

Cancer Inst. 2011 Mar 16;103(6):478-88.https://www.ncbi.nlm.nih.gov/pubmed/21398619https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107729/

6) Fisher B, Costantino JP, Wickerham DL et al Tamoxifen for prevention of breast cancer: report ofthe National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep16;90(18):1371-88. https://www.ncbi.nlm.nih.gov/pubmed/97478687) Cuzick J, Powles T, Ve ronesi U et al. Overview of the main outcomes in breast-cancer preventiontrials. Lancet. 2003 Jan 25;361(9354):296-300. https://www.ncbi.nlm.nih.gov/pubmed/125598638) Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators.Tamoxifen for prevention of breast cancer extended long-term follow-up of the IBIS-I breast cancerprevention trial. Lancet Oncol. 2015 Jan;16(1):67-75.https://www.ncbi.nlm.nih.gov/pubmed/25497694

P54-57

Web 資料あり参考文献1. 薬害オンブズパースン会議、WHO ワクチン安全性諮問委員会（GACVS）の HPV ワクチンに関する声明（2015 年 12 月 17 日付）に対する反論、http://www.yakugai.gr.jp/topics/file/20161102_refutation_of_gacvs_statement_on_safety_of_hpv_vaccines_20151217_japanese.pdf2. 1. Gøtzsche PC, Jefferson T, Auken M, Brinth L. Complaint to the European ombudsman overmaladministration at the European Medicines Agency (EMA) in relation to the safety of the HPV vaccines.http://nordic.cochrane.org/sites/nordic.cochrane.org/files/public/uploads/ResearchHighlights/Complaint-to-ombudsman-over-EMA.pdf [accessed 27.01.17]3. Quinn M, Babb P, Jones J, Allen E.Effect of screening on incidence of and mortality from cancer ofcervix in England: evaluation based on routinely collected statistics. BMJ. 1999 Apr 3;318(7188):904-8.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC27810/4. Shastri SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, Badwe RA. Effect of VIA screening byprimary health workers: randomized controlled study in Mumbai, India.J Natl Cancer Inst. 2014 Mar;106(3):dju009. doi: 10.1093/jnci/dju0https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju0095. HPV screening for cervical cancer in rural India.

4

Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG,Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N,Dinshaw KA. N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516.http://www.nejm.org/doi/pdf/10.1056/NEJMoa08085166. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, FayetteJM, Cherian J.Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu,India: a cluster-randomised trial.Lancet. 2007 Aug 4;370(9585):398-406.https://www.ncbi.nlm.nih.gov/pubmed/176790177. 人口動態統計 http://www.e-stat.go.jp/SG1/estat/OtherList.do?bid=000001041646&cycode=78. 浜六郎ら、子宮頸がんの疫学と HPV ワクチン、The Informed Prescriber 2013:28(2):27-31. http://www.npojip.org/contents/link/tip-free/2013/2013_04.pdf9. Kripke DF, Garfinkel L, Wingard DL et al. Mortality associated with sleep duration and insomnia. ArchGen Psychiatry. 2002 Feb;59(2):131-6. https://www.ncbi.nlm.nih.gov/pubmed/1182513310. Klerman EB, Dijk DJ. Age-related reduction in the maximal capacity for sleep--implications forinsomnia. Curr Biol. 2008 Aug 5;18(15):1118-23. file:///C:/Users/Roku/Downloads/srep35812.pdf11. Kitamura S, Katayose Y, Nakazaki K et al. Estimating individual optimal sleep duration andpotential sleep debt. Sci Rep. 2016 Oct 24;6:35812. http://www.nature.com/articles/srep3581212.浜六郎、「薬のやめ方」事典、三五館、2017

p57

p.58-59

5

参考文献

1) Laing KJ et al. Zoster vaccination increases the breadth of CD4+ T cells responsive to Varicella

zoster virus. J Infect Dis 2015;212:1022-31.

https://www.ncbi.nlm.nih.gov/pubmed/25784732

2) Gagliardi AM et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database

Syst Rev. 2016 Mar 3;3:CD008858.


3) Tseng HF et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster

disease. JAMA 2011;305:160-6. https://www.ncbi.nlm.nih.gov/pubmed/21224457

4) Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

N Engl J Med 2005;352:2271-84.

5) Schmader KE et al. Persistence of the efficacy of zoster vaccine in the shingles prevention

study and the short-term persistence substudy. Clin Infect Dis 2012;55:1320-8.


6) Morrison VA et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis

2015;60:900-9. https://www.ncbi.nlm.nih.gov/pubmed/25416754

7) Lai YC, Yew YW. Severe autoimmune adverse events post herpes zoster vaccine: a

case-control study of adverse events in a national database. J Drugs Dermatol 2015;14:681–4.


8) Tseng HF et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an

immunocompetent elderly population. J Infect Dis 2012;206:190-6

https://www.ncbi.nlm.nih.gov/pubmed/22669900 .

9) Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann

Intern Med 2015;163:489-97. https://www.ncbi.nlm.nih.gov/pubmed/26344036

10) Cunningham AL et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age

or older. N Engl J Med 2016;375:1019-32.


11) 浜六郎、アジュバントって何？薬のチェックは命のチェック 2014：14(53)：47-67.

http://www.npojip.org/contents/book/mag053.html

http://www.npojip.org/sokuho/140128.html (Free)

6

P62

以下記事を

参考文献参考文献

1) Prescrire Editorial Staff “Irritable bowel syndrome. A mild disorder; purely symptomatictreatment”Prescrire Int 2009; 18 (100): 75-79.2) EMA - CHMP “Assessment report for linaclotide. EMEA/H/C/2490”20 September 2012: 3) USFDA - CDER “Application Number: 202811Orig1s000 - Medical Review(s)”16 August 2012:4) Rao S et al. “A 12-week, randomized, controlled trial with a 4-week randomized withdrawal periodto evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation”Am JGastroenterol 2012; 107 (11): 1714-1724.5) Chey WD et al. “Linaclotide for irritable bowel syndrome with constipation: a 26-week,randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety”Am JGastroenterol 2012; 107 (11): 1702-1712.6) European Commission “SPC-Constella”20 February 2014: 11 pages.7) Lembo AJ et al. “Two randomized trials of linaclotide for chronic constipation”N Eng J Med 2011;365 (6): 527-536.8) Lin JE, Valentino M, Marszalowicz G et al. Bacterial heat-stable enterotoxins: translation ofpathogenic peptides into novel targeted diagnostics and therapeutics. Toxins (Basel). 2010Aug;2(8):2028-54. https://www.ncbi.nlm.nih.gov/pubmed/220696719)Ford AC, Suares NC.Effect of laxatives and pharmacological therapies in chronic idiopathicconstipation: systematic review and meta-analysis. Gut 2011;60(2):209-218.

10) 薬のチェックTIP 編集委員会、ルビプロストン(商品名:アミティーザ):使用不可、害が大

きすぎる、薬のチェックTIP、2015:15(59): 55-57 http://www.npojip.org/chk_tip.html#No59

P63

Prescrire 評価薬のチェック TIP 評価

7

P65

参考文献1) Health Canada “Summary safety review Over the counter products containingpseudoephedrine-Assessing the potential risk of inflammation and injury of the large intestine due toinsufficient blood supply(ischemic coliris)”24 February 2016; 2pages.2) Prescrire Redaction “16-1-2 Patients sous vasoconstricteur decongestionnant”Rev Prescrire2016;36(386 suppl Interactions medicamenteuses).3) Sherid M et al. “Pseudoephedrine-induced ischemic colitis :case report and literature review”JDigest Dis 2014; 15: 276-280.4) Prescrire Editorial Staff “Ischaemic colitis on pseudoephedrine” Prescrire Int 2001; 10(54):117.

P66

以下本文を

8

参考文献

1) ANSM “Reunion du comite technique de pharmacovigilance, compte rendu de la seance du 15decembre 2015. Suivi batuibak de ogarnacivugukabce des soecuakutes a base de sofosbuvir etdaclatasvir Sovaldi Harvoni Daklinza“9 January 2016; 18-21.2) Renard S et al. “Severe pulmonary arterial hypertension in patients treated for hepatitis C withsofosbuvir“Chest 2016; 149(3): 69-73.3) Savale L et al. “Direct-acting antiviral medications for hepatitis C virus infection and pulmonaryarterial hypertension”Chest 2016; 150(1):256-258.4) Prescrire Redaction “Notice Harvoni (sofosbuvir+ledipasvir):quasiabsence d’information surleseffects indesirables“Rev prescrire 2016; 36(389):223.5) European Commission “SPC-Harvoni“22 July 2016; 53pages.6) European Commission “SPC-Sovaldi”28 January 2016; 44pages.

P66

参考文献1) Health Canada “Summary Safety Review AVASTIN(bevacizumab)-Assessing the Potential Risk ofIrreversible Vocal Cord Damage(vocal cord necrosis)”30 November 2015 www.sc-hc.gc.caaccessed13 February 2016:2page2) Kountourakis P et al.”Voice disorders induced by bevacizumab administration in an ovarian cancerpatient: an underestimated and rare toxicity”Hematol Oncol Stem Cell Ther 2014;7(3):123-124.3) Saavedra E et al. “Dysphonia Induced by anti-angiogenic compounds” Investigational New Drugs2014;32(4):774-782.

P67

参考文献1) FDA ”Drug Safety Communication: FDA warns about several safety issues with opioid painmedicines”22 March 2016: 11pages.2) Debono M et al.”Tramadol-induced adrenalinsufficiency”Eur J Clin Pharmacol 2011:67:865-867.3) “Opioid analgesics”. In:”Martindale The Complete Drug Reference”The Pharmaceutical press,London. www.medicinescomplete.com accessed 17 Aprill 2016:21pages.4) Prescrire Editorial Staff “Opioid and hypogonadism”Prescrire Int. 2012;21(126):98-99.5) Lee AS and Twigg SM “Opioid-induced secondary adrenal insufficiency presenting ashypercalcaemia”Endocrinol Diabetes Metab 2015:5pages.6) “Policola C et al. “Adrenal insufficiency in acute oral opiate therapy” Endocrinol Diabetes Metab2014:3pages.

9

P68-69

P70

連載：医薬品危険性情報あれこれ日本の国立医薬品食品衛生研究所が発行している「医薬品安全性情報（海外規制

機関）」から薬剤の害反応を紹介し、本誌編集委員がコメントする。

【WHO】デノスマブ:血管炎

【カナダHealth Canada】インターフェロンß製剤:肺動脈性肺高血圧

【英MHRA】C型肝炎治療用の直接作用型抗ウイルス剤:ビタミンK拮抗剤との相互作

用によりPT-INR変動が生じるリスク

P71

「つくられた恐怖の点滴殺人事件守大助さんは無実だ」

P72

編集後記

2017 年5 月(no71）の記事要旨と参考文献 · 1 2017 年5...

Documents